GLP-1 Medications and Fertility: Current Research

The relationship between GLP-1 medications and fertility is one of the more interesting emerging areas in reproductive medicine. Weight loss itself improves fertility outcomes, but semaglutide and tirzepatide appear to have direct effects on reproductive hormones that go beyond what weight loss alone would explain. For women planning a pregnancy, navigating a fertility workup, or simply trying to understand how these medications interact with their reproductive system, here’s what the current research actually shows.

Why Weight and Fertility Are Linked

Before getting into GLP-1 specifics, it helps to understand the underlying biology. Excess adipose tissue disrupts the hormonal signaling involved in ovulation. Fat cells produce estrogen independently of the ovaries, which interferes with the hypothalamic-pituitary-ovarian axis, the feedback loop that regulates the menstrual cycle. Elevated insulin, common in women with obesity, drives up androgen production in the ovaries, further disrupting ovulation.

The result is that women with obesity have significantly higher rates of anovulation, irregular cycles, and conditions like PCOS. They also have lower success rates with assisted reproduction. Losing even 5%–10% of body weight has been shown to restore ovulatory function in women who had stopped ovulating.

GLP-1 medications address both sides of this problem: they drive meaningful weight loss, and they directly improve insulin sensitivity. That dual action is why reproductive endocrinologists are paying close attention.

What GLP-1 Receptors Do in the Reproductive System

GLP-1 receptors aren’t just found in the gut and brain. Research has identified them in the ovaries, uterus, and hypothalamus. This means semaglutide may have direct effects on reproductive tissue, not just indirect effects through weight loss.

Animal studies have shown that GLP-1 receptor activation in the hypothalamus influences the release of GnRH (gonadotropin-releasing hormone), which sits at the top of the reproductive hormone cascade. Whether this translates meaningfully to human fertility outcomes is still being studied, but it suggests the mechanism is more complex than simply “lose weight, ovulate better.”

A 2023 review published in Reproductive Biology and Endocrinology examined GLP-1 receptor distribution across reproductive tissues and concluded that direct ovarian effects are biologically plausible and warrant further clinical investigation.

GLP-1 and PCOS: The Strongest Evidence

The clearest fertility-related evidence for GLP-1 medications comes from PCOS research. Women with PCOS have insulin resistance as a core feature, and GLP-1 medications address this directly.

Multiple studies have shown that semaglutide treatment in women with PCOS leads to reductions in testosterone and LH levels, improvements in menstrual regularity, and in some cases restoration of ovulation in women who had been anovulatory. One small but notable trial found that women with PCOS on semaglutide saw cycle regularity improve within three to four months of starting treatment.

For a deeper look at how GLP-1 medications specifically address PCOS mechanisms, weight loss for women with PCOS covers the treatment landscape in detail.

Fertility Treatment Outcomes and Weight Loss

Beyond PCOS, the broader question is whether GLP-1-assisted weight loss improves assisted reproduction outcomes. The answer, based on available data, is yes.

A landmark study published in Human Reproduction followed women with obesity undergoing IVF and found that those who lost at least 10% of body weight before their cycle had significantly higher clinical pregnancy rates and live birth rates compared to matched controls who did not lose weight. While this study wasn’t specific to GLP-1 medications, it establishes the mechanism: weight loss before fertility treatment improves outcomes.

GLP-1 medications are now being used strategically by some reproductive endocrinologists as a pre-IVF intervention, with patients losing weight over six to twelve months before proceeding with embryo transfer. This approach is gaining traction particularly for women who have had failed cycles and whose BMI was flagged as a contributing factor.

The Unintended Pregnancy Question

One finding that has caught attention in both clinical and patient communities: women on GLP-1 medications have reported unintended pregnancies at a rate that suggests these medications may restore fertility faster than expected.

The likely explanation is the rapid improvement in ovulatory function, particularly in women with PCOS or insulin resistance who had assumed they were subfertile. A woman who hadn’t had a regular cycle in years may begin ovulating again within weeks of starting semaglutide, before she or her provider has had a chance to address contraception.

This is a clinically important point. Women who are not trying to conceive should discuss contraception with their provider when starting GLP-1 treatment. And as covered in the Ozempic while trying to conceive article, oral contraceptive absorption may be affected by GLP-1’s impact on gastric emptying, making this conversation even more important.

What Research Does Not Yet Show

It’s worth being clear about the limits of current evidence. Most studies on GLP-1 and fertility are small, short-term, or focused on PCOS rather than the general population. There are no large randomized controlled trials specifically examining GLP-1 medication use as a fertility intervention.

We also don’t have good data on what happens to fertility markers after stopping GLP-1 medications, whether the hormonal improvements persist, or whether they require continued treatment to maintain. These are active research questions.

What we can say is that the biological plausibility is strong, the early clinical signals are encouraging, and the indirect benefit through weight loss is well-established.

Timing GLP-1 Treatment Around Fertility Goals

For women who want to use GLP-1 medications as part of their fertility preparation, the general framework looks like this. Use the medication to achieve target weight loss, ideally 10%–15% of starting body weight. Stop the medication at least two months before actively trying to conceive or before a planned embryo transfer. Maintain results through structured nutrition and activity during the active TTC window.

Consider this scenario: a 29-year-old woman with a BMI of 33 and irregular cycles starts compounded tirzepatide with her reproductive endocrinologist’s support. Over nine months she loses 31 pounds, her cycles become regular for the first time in three years, and her AMH levels improve slightly. She stops tirzepatide two months before her planned IUI cycle. Her first IUI results in a successful pregnancy.

That sequence, strategic use followed by a planned stop, is increasingly how fertility specialists are integrating these medications.

Having the Right Conversation With Your Provider

If fertility is part of your health picture, it needs to be part of your GLP-1 conversation from the start. A prescriber who knows your reproductive goals can help you set realistic timelines, plan your stop date, and think through nutrition support for the transition period.

TrimRx providers work with patients on exactly these kinds of nuanced situations. To find out whether you’re a candidate for GLP-1 treatment given your health history and goals, start with the intake assessment.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.